|
1) Gatzoulis MA, Hechter S, Siu SC, et al. Outpatient clinics for adults with congenital heart disease: increasing workload and evolving patterns of referral. Heart. 1999; 81: 57-61
|
|
|
|
2) Perloff JK. Congenital heart disease in adults. A new cardiovascular subspecialty. Circulation. 1991; 84: 1881-90
|
|
|
|
|
|
3) Bedard E, Shore DF, Gatzoulis MA. Adult congenital heart disease: a 2008 overview. Br Med Bull. 2008; 85: 151-80
|
|
|
|
|
4) Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. The DECODE study group. European Diabetes Epidemiology Group. Diabetes Epidemiology: Collaborative analysis Of Diagnostic criteria in Europe. Lancet. 1999; 354: 617-21
|
|
|
|
|
|
5) Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and Management of the Metabolic Syndrome: An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation. 2005; 112: 2735-52
|
|
|
|
|
|
6) Bolger AP, Coats AJ, Gatzoulis MA. Congenital heart disease: the original heart failure syndrome. Eur Heart J. 2003; 24: 970-6
|
|
|
|
|
|
7) Hu G, Qiao Q, Tuomilehto J, et al. Prevalence of the metabolic syndrome and its relation to all-cause and cardiovascular mortality in nondiabetic European men and women. Arch Intern Med. 2004; 164: 1066-76
|
|
|
|
|
|
8) Barker DJ, Eriksson JG, Forsen T, et al. Fetal origins of adult disease: strength of effects and biological basis. Int J Epidemiol. 2002; 31: 1235-9
|
|
|
|
|
|
9) Barker DJ, Osmond C, Forsen TJ, et al. Trajectories of growth among children who have coronary events as adults. N Engl J Med. 2005; 353: 1802-9
|
|
|
|
|
|
10) Eriksson JG, Forsen T, Tuomilehto J, et al. Catch-up growth in childhood and death from coronary heart disease: longitudinal study. BMJ. 1999; 318: 427-31
|
|
|
|
|
|
11) Barker DJ. Fetal origins of coronary heart disease. BMJ. 1995; 311: 171-4
|
|
|
|
|
|
12) Swan JW, Anker SD, Walton C, et al. Insulin resistance in chronic heart failure: relation to severity and etiology of heart failure. J Am Coll Cardiol. 1997; 30: 527-32
|
|
|
|
|
|
13) Witteles RM, Tang WH, Jamali AH, et al. Insulin resistance in idiopathic dilated cardiomyopathy: a possible etiologic link. J Am Coll Cardiol. 2004; 44: 78-81
|
|
|
|
|
|
14) Ingelsson E, Sundstrom J, Arnlov J, et al. Insulin resistance and risk of congestive heart failure. JAMA. 2005; 294: 334-41
|
|
|
|
|
|
15) Gradman A, Deedwania P, Cody R, et al. Predictors of total mortality and sudden death in mild to moderate heart failure. J Am Coll Cardiol. 1989; 14: 564-70
|
|
|
|
|
|
16) Chattipakorn N, Incharoen T, Kanlop N, et al. Heart rate variability in myocardial infarction and heart failure. Int J Cardiol. 2007; 120: 289-96
|
|
|
|
|
|
17) Schrier RW, Abraham WT. Hormones and hemodynamics in heart failure. N Engl J Med. 1999; 341: 577-85
|
|
|
|
|
|
18) Katz SD, Hryniewicz K, Hriljac I, et al. Vascular endothelial dysfunction and mortality risk in patients with chronic heart failure. Circulation. 2005; 111: 310-4
|
|
|
|
|
|
19) O'Neill JO, Young JB, Pothier CE, et al. Peak oxygen consumption as a predictor of death in patients with heart failure receiving beta-blockers. Circulation. 2005; 111: 2313-8
|
|
|
|
|
|
20) Norrelund H, Wiggers H, Halbirk M, et al. Abnormalities of whole body protein turnover, muscle metabolism and levels of metabolic hormones in patients with chronic heart failure. J Intern Med. 2006; 260: 11-21
|
|
|
|
|
|
21) von Haehling S, Doehner W, Anker SD. Nutrition, metabolism, and the complex pathophysiology of cachexia in chronic heart failure. Cardiovasc Res. 2007; 73: 298-309
|
|
|
|
|
|
22) Barr EL, Zimmet PZ, Welborn TA, et al. Risk of cardiovascular and all-cause mortality in individuals with diabetes mellitus, impaired fasting glucose, and impaired glucose tolerance: the Australian Diabetes, Obesity, and Lifestyle Study (AusDiab). Circulation. 2007; 116: 151-7
|
|
|
|
|
|
23) Bartnik M, Malmberg K, Norhammar A, et al. Newly detected abnormal glucose tolerance: an important predictor of long-term outcome after myocardial infarction. Eur Heart J. 2004; 25: 1990-7
|
|
|
|
|
|
24) Chiasson JL, Josse RG, Gomis R, et al. STOP-NIDDM Trial Research Group. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA. 2003; 290: 486-94
|
|
|
|
|
|
25) Kawano H, Motoyama T, Hirashima O, et al. Hyperglycemia rapidly suppresses flow-mediated endothelium-dependent vasodilation of brachial artery. J Am Coll Cardiol. 1999; 34: 146-54
|
|
|
|
|
|
26) Ceriello A, Taboga C, Tonutti L, et al. Evidence for an independent and cumulative effect of postprandial hypertriglyceridemia and hyperglycemia on endothelial dysfunction and oxidative stress generation: effects of short- and long-term simvastatin treatment. Circulation. 2002; 106: 1211-8
|
|
|
|
|
|
27) Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein HC, Miller ME, Byington RP, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008; 358: 2545-59
|
|
|
|
|
|
28) Witteles RM, Fowler MB. Insulin-resistant cardiomyopathy clinical evidence, mechanisms, and treatment options. J Am Coll Cardiol. 2008; 51: 93-102
|
|
|
|
|
|
29) Bertrand L, Horman S, Beauloye C, et al. Insulin signalling in the heart. Cardiovasc Res. 2008; 79: 238-48
|
|
|
|
|
|
30) Schwenk RW, Luiken JFP, Bonen A, et al. Regulation of sarcolemmal glucose and fatty acid transporters in cardiac disease. Cardiovasc Res. 2008; 79: 249-58
|
|
|
|
|
|
31) An Di, Rodrigues B. Role of changes in cardiac metabolism in development of diabetic cardiomyopathy. Am J Physiol Heart Circ Physiol. 2006; 291: H1489-506
|
|
|
|
|
|
32) Young ME, McNulty P, Taegtmeyer H. Adaptation and maladaptation of the heart in diabetes: Part II: potential mechanisms. Circulation. 2002; 105: 1861-70
|
|
|
|
|
|
33) Opie LH. The metabolic vicious cycle in heart failure. Lancet. 2004; 364: 1733-4
|
|
|
|
|
|
34) Relationship of atherosclerosis in young men to serum lipoprotein cholesterol concentrations and smoking. A preliminary report from the Pathobiological Determinants of Atherosclerosis in Youth (PDAY) Research Group. JAMA. 1990; 264: 3018-24
|
|
|
|
|
|
35) Fyfe A, Perloff JK, Niwa K, et al. Cyanotic congenital heart disease and coronary artery atherogenesis. Am J Cardiol. 2005; 96: 283-90
|
|
|
|
|
|
36) Rauchhaus M, Coats AJ, Anker SD. The endotoxin-lipoprotein hypothesis. Lancet. 2000; 356: 930-3
|
|
|
|
|
|
37) Rauchhaus M, Clark AL, Doehner W, et al. The relationship between cholesterol and survival in patients with chronic heart failure. J Am Coll Cardiol. 2003; 42: 1933-40
|
|
|
|
|
|
38) Hait G, Corpus M, Lamarre FR, et al. Alteration of glucose and insulin metabolism in congenital heart disease. Circulation. 1972; 46: 333-46
|
|
|
|
|
|
39) Coppack SW, Jensen MD, Miles JM. In vivo regulation of lipolysis in humans. J Lipid Res. 1994; 35: 177-93
|
|
|
|
|
|
40) Howard BV. Insulin actions in vivo: insulin and lipoprotein metabolism. In: Alberti KGMM, Zimmet P, DeFronzo RA, et al, editors. International textbook of diabetes mellitus, 2nd ed. Vol. 1. New York: John Wiley and Sons; 1997. p. 531-9
|
|
|
|
|
|
41) Barter P, Gotto AM, LaRosa JC, et al. Treating to New Targets Investigators. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med. 2007; 357: 1301-10
|
|
|
|
|
|
42) Howard BV, Robbins DC, Sievers ML, et al. LDL cholesterol as a strong predictor of coronary heart disease in diabetic individuals with insulin resistance and low LDL: The Strong Heart Study. Arterioscler Thromb Vasc Biol. 2000; 20: 830-5
|
|
|
|
|
|
43) Curtis JP, Selter JG, Wang Y, et al. The obesity paradox: body mass index and outcomes in patients with heart failure. Arch Intern Med. 2005; 165: 55-61
|
|
|
|
|
|
44) Tjonna AE, Lee SJ, Rognmo O, et al. Aerobic interval training versus continuous moderate exercise as a treatment for the metabolic syndrome. A pilot study. Circulation. 2008; 118: 346-54
|
|
|
|
|
|
45) Di Napoli P, Di Giovanni P, Gaeta MA, et al. Trimetazidine and reduction in mortality and hospitalization in patients with ischemic dilated cardiomyopathy: a post hoc analysis of the Villa Pini d'Abruzzo Trimetazidine Trial. J Cardiovasc Pharmacol. 2007; 50: 585-9
|
|
|
|
|